GlassScriptPhysician profile
Paul M Caracappa
NPI 1366462459
$9,154.90
in general payments reported to CMS, 2019-2025
44 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $1,060 · 2021: $1,369 · 2022: $1,814 · 2023: $1,414 · 2024: $1,351 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,217.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,369.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,000.84 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $891.53 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $890.61 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Bausch Health US, LLC | $658.86 | 2019-2025 | Aplenzin, Wellbutrin |
| Medtronic, INC. | $581.49 | 2022-2023 | Inpen Smart Insulin Delivery System |
| Exact Sciences Corporation | $444.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $420.26 | 2019-2024 | Verquvo, Gardasil 9, Lagevrio |
| Amarin Pharma, INC. | $342.20 | 2020-2022 | |
| Glaxosmithkline, LLC. | $284.01 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $277.02 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.14 | 2019-2024 | Cycloset |
| Pfizer INC. | $244.34 | 2019-2025 | |
| Amgen INC. | $228.85 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.40 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Caracappa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.